BackgroundValproic acid (VPA) is an important antiepileptic medication, but its continuous use is limited by serious neurotoxic side effects, including cognitive impairment and neuronal cell death. In this study, we examined how co-administering VPA with melatonin (MEL) and vitamin B6 could help control seizures while avoiding an increase in VPA-related neurotoxicity, using PTZ-induced seizures as a model.MethodsMale Wistar mice were assigned at random to five groups (n=8 in each group): control animals receiving saline, animals treated with VPA at 250 mg/kg, animals treated with VPA at 500 mg/kg, animals given VPA 250 mg/kg combined with MEL (10 mg/kg) and B6 (50 mg/kg), and animals given VPA 500 mg/kg combined with MEL and B6. Injections were given intraperitoneally once daily for 14 days. After treatment, seizures were triggered with PTZ at 35 mg/kg. Seizure outcomes, including latency, overall duration, and severity, were determined using the Modified Racine Scale. Behavioral performance was evaluated with Novel Object Recognition (NOR), Novel Texture Recognition (NTR), shuttle box avoidance, and the Elevated Plus Maze (EPM). Finally, histopathological alterations in the hippocampus were assessed using Nissl staining.ResultsThe combination therapy (VPA 500 mix) markedly increased seizure onset latency (70.0 ± 0.0 s vs. 44.7 ± 4.9 s in controls, p<0.01) and shortened seizure duration (586.0 ± 57.8 s vs. 961.2 ± 114.7 s, p<0.01) compared with the control group. All groups treated with VPA completely eliminated stage 6 seizures. The VPA 500 mix group also showed better cognitive outcomes, with a 192% rise in the NOR discrimination index and a 183% increase in the shuttle box avoidance index compared to controls (p<0.01). On histopathological analysis, VPA 500 mix preserved 71% of intact neurons and brought the degenerated cell ratio back toward normal when compared with VPA 500 monotherapy (p<0.001). Anxiolytic effects were evident as well, indicated by increased time spent in the open arms of the EPM, while locomotor activity remained unchanged.ConclusionCoadministration of VPA with melatonin and vitamin B6 produces synergistic effects, significantly improving seizure control, preserving cognitive function, and providing robust neuroprotection. This triple combination represents a promising adjunctive strategy to overcome VPA-induced neurotoxicity in epilepsy management.